Ensysce Biosciences Announces Successful Completion of Clinical Study for Pain Medication with Overdose Protection, Amgen and TScan Therapeutics Collaborate to Identify Antigens for Crohn's Disease Treatment
- May 09th, 2023
- 600 views
Ensysce Biosciences, Inc. (Nasdaq: ENSC) has completed the clinical study of its first pain medication with overdose protection, PF614-MPAR, known as PF614-MPAR-101. The final Part B of the study showed that PF614-MPAR effectively reduced opioid delivery when three or more doses were consumed simultaneously, with dose escalation from 25 to 200 mg (1 to 8 dose units).
In other news, Amgen (Nasdaq: AMGN) and TScan Therapeutics, Inc. (Nasdaq: TCRX) have announced a collaboration to identify antigens recognized by T cells in Crohn's disease patients. TScan will receive a $30 million upfront payment and may receive over $500 million in success-based preclinical, clinical, regulatory and commercial milestones. Additionally, tiered single-digit royalty payments will be made.
$ENSC is trading at $5.96, up by 73.33% or $2.52. Meanwhile, $TCRX is trading at $4.25, up by 97.67% or $2.10.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
February 27th, 2026February 26th, 2026
Treasury Sanctions Nicaraguan Officials Enabling the Murillo-Ortega Dictatorship's Repression
February 26th, 2026Kansas City Storm Names Cecil Stockdale as Head Coach for 2026 NJCP Season
February 26th, 2026Dallas Stampede Announces Open Tryouts for Scholarship Opportunities
February 25th, 2026
Member Login